GSK to buy pulmonary hypertension biotech 35Pharma for $950M
葛兰素史克拟以9.5亿美元收购肺动脉高压生物技术公司35Pharma

GSK said on Wednesday that it is buying 35Pharma for $950 million, picking up the Canadian biotech’s pulmonary hypertension drug program — and potentially dipping its toes into investigating weight loss drugs that avoid muscle loss.
葛兰素史克周三表示，将以9.5亿美元收购35Pharma，拿下这家加拿大生物技术公司的肺动脉高压药物项目——并有望试水避免肌肉流失的减重药物研究。